Morgan Stanley set a €70.00 ($81.40) target price on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research note released on Thursday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
Several other equities research analysts have also weighed in on the company. Jefferies Financial Group reiterated a buy rating and issued a GBX 99 ($1.29) price objective on shares of in a research note on Friday, June 28th. Barclays reiterated a hold rating and issued a $14.00 price objective on shares of MACOM Technology Solutions in a research note on Thursday, June 20th. HSBC set a €101.00 ($117.44) price objective on Grenke and gave the company a buy rating in a research note on Thursday, April 25th. Deutsche Bank set a €230.00 ($267.44) price objective on adidas and gave the company a neutral rating in a research note on Tuesday, May 7th. Finally, Kepler Capital Markets set a €80.00 ($93.02) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a research note on Thursday, May 2nd. Seven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Fresenius Medical Care AG & Co. KGaA presently has an average rating of Buy and a consensus price target of €82.57 ($96.01).
FME stock opened at €69.70 ($81.05) on Thursday. Fresenius Medical Care AG & Co. KGaA has a 1-year low of €55.44 ($64.47) and a 1-year high of €91.74 ($106.67). The company has a market cap of $21.28 billion and a price-to-earnings ratio of 10.85. The firm has a 50 day moving average of €68.10. The company has a debt-to-equity ratio of 100.05, a quick ratio of 0.67 and a current ratio of 1.02.
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Read More: Strike Price
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.